{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-058118","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.352964+00:00","generated_at":"2026-06-18T15:01:22.091953+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Akebia amends Auryxia supply agreement with Siegfried; extends term to Dec 2024 with option to 2026","bullets":["Amendment No. 5 to Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA.","Akebia commits to purchase minimum quantity of Auryxia drug substance at predetermined price.","Term extended to Dec 31, 2024; Company has option to extend to Dec 31, 2026 with 12 months notice.","No other financial terms disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-058118","json":"https://secwatch.observer/filing/0001193125-23-058118.json","markdown":"https://secwatch.observer/filing/0001193125-23-058118.md","text":"https://secwatch.observer/filing/0001193125-23-058118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/0001193125-23-058118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/d447916d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:01:22.091953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b04bcb4935ad94b39022e10a7e2070335acf979","claim":"Akebia Therapeutics, Inc. amended Amendment No. 5 to Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA (effective 2022-02-28).","evidence_excerpt":"On February 28, 2022, Keryx Biopharmaceuticals, Inc., a wholly-owned subsidiary of Akebia Therapeutics, Inc. (the “Company”), and Siegfried Evionnaz SA (“Siegfried”) entered into Amendment No. 5 to Master Manufacturing Services and Supply Agreement (the “Amendment”), which further amends the Master Manufacturing Services and Supply Agreement dated December 20, 2017 (as amended, the “Supply Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/0001193125-23-058118-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Siegfried Evionnaz SA"},{"label":"Effective","value":"2022-02-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}